Literature DB >> 17432073

Lessons learnt in the management of Wegener's Granulomatosis: long-term follow-up of 60 patients.

E L Sproson1, N S Jones, M Al-Deiri, P Lanyon.   

Abstract

OBJECTIVE: To assess all patients with Wegener's Granulomatosis treated in Nottingham, with particular focus on relapse rate and the useful predictors of relapse. We evaluated how well the findings of nasal examination correlated with disease relapse compared to other parameters such as c-ANCA, ESR and CRP. Presenting features, diagnosis, adverse effects of treatment and mortality rate, were also studied.
DESIGN: Retrospective examination of 60 patient notes, diagnosed and treated for Wegener's granulomatosis at Queen's Medical Centre, Nottingham. The mean follow up period was 8.7 years. Relapse was defined as per the European Vasculitis Study criteria.
RESULTS: cANCA is a useful test at presentation for diagnosis but a negative result does not rule out the disease. Those presenting with ENT symptoms alone may have less raised inflammatory markers but similar cANCA titres as patients with multi-system disease. However, at relapse, patients with ENT disease alone have similar levels of inflammatory markers as those with multi-system relapse. Nasal examination was useful at monitoring the presence of disease activity where the nasal lining is affected.
CONCLUSIONS: Signs of intranasal disease in the form of granular tissue, erythema and bleeding to light touch and crusting over granulation tissue are good predictors of disease activity. A raised cANCA, ESR or CRP provide supporting information about disease activity but if they are negative this does not exclude active disease. cANCA levels were as elevated at relapse in patients who had isolated nasal symptoms and signs as in those with evidence of systemic disease. Low relapse rates were found possibly due to prompt and rigorous initial immunosuppression even in limited disease. This seemed to lead to less progression of patients to multi-system disease and hence a low mortality rate of 5%.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17432073

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  14 in total

1.  Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Paul A Monach; Gunnar Tomasson; Ulrich Specks; John H Stone; David Cuthbertson; Jeffrey Krischer; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Ikle; Cees G M Kallenberg; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Yi-Zhong Gu; Ronald D Snyder; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2011-12

2.  Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.

Authors:  Paul A Monach; Roscoe L Warner; Gunnar Tomasson; Ulrich Specks; John H Stone; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Iklé; Cees G M Kallenberg; Jeffrey Krischer; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Kent J Johnson; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2012-09-12       Impact factor: 19.103

3.  Granulomatosis with polyangiitis affecting the skull base and manifesting as spontaneous skull base osteomyelitis.

Authors:  Laura Harrison; Jeremy Mcnally; Rogan Corbridge
Journal:  BMJ Case Rep       Date:  2016-02-29

4.  Structured clinical assessment of the ear, nose and throat in patients with granulomatosis with polyangiitis (Wegener's).

Authors:  Marcos Martinez Del Pero; Niels Rasmussen; Afzal Chaudhry; Piyush Jani; David Jayne
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-18       Impact factor: 2.503

5.  Gingival hyperplasia being the first sign of Wegener's granulomatosis.

Authors:  Víctor Aravena; Víctor Beltrán; Mario Cantín; Ramón Fuentes
Journal:  Int J Clin Exp Med       Date:  2014-08-15

6.  Increased histopathological yield for granulomatosis with polyangiitis based on nasal endoscopy of suspected active lesions.

Authors:  Olga Beltrán Rodríguez-Cabo; Edgardo Reyes; Jorge Rojas-Serrano; Luis Felipe Flores-Suárez
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-11       Impact factor: 2.503

7.  Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes.

Authors:  Mara Felicetti; Diego Cazzador; Roberto Padoan; Alfonso Luca Pendolino; Chiara Faccioli; Ennio Nardello; Alvise Berti; Marina Silvestrini; Giuseppe Paolazzi; Giuliano Brunori; Elisabetta Zanoletti; Enzo Emanuelli; Alessandro Martini; Franco Schiavon
Journal:  Clin Rheumatol       Date:  2018-02-20       Impact factor: 2.980

Review 8.  Clinic manifestations in granulomatosis with polyangiitis.

Authors:  A Greco; C Marinelli; M Fusconi; G F Macri; A Gallo; A De Virgilio; G Zambetti; M de Vincentiis
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

9.  Nasal surgery in patients with systemic disorders.

Authors:  Florian Sachse; Wolfgang Stoll
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2011-04-27

10.  Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis.

Authors:  Paul A Monach; Philipp Kümpers; Alexander Lukasz; Gunnar Tomasson; Ulrich Specks; John H Stone; David Cuthbertson; Jeffrey Krischer; Simon Carette; Linna Ding; Gary S Hoffman; David Iklé; Cees G M Kallenberg; Nader A Khalidi; Carol A Langford; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Marion Haubitz; Peter A Merkel
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.